Surrozen

IPO

Restoring Vision Through the Science of Renewal

Public · South San Francisco, United States · Founded 2016 · $133.0M raised

Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$133.0M
Last Round
$50.0M Series CJun 2020
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 3 investors for this company. The full record is or through the API.

About

Surrozen is a clinical-stage biotechnology company pioneering Wnt-based therapeutics designed to repair and restore tissue function. The company's multifunctional biologics selectively activate Wnt signaling for ophthalmic diseases including diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema. Founded in 2016, Surrozen focuses on helping patients preserve and regain vision through its regenerative medicine platform.

Summary

Surrozen is a Biotech company based in South San Francisco, United States, founded in 2016. It has raised $133.0M in total across 3 rounds, most recently a $50.0M Series C round in Jun 2020. Investors include The Column Group, Venrock and Euclidian Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondary MarketMar 2025

Sign up to see all 4 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Surrozen on Indexed.vc
<a href="https://indexed.vc/companies/surrozen"><img src="https://indexed.vc/api/badge/company/surrozen" alt="Surrozen on Indexed.vc" width="260" height="76" /></a>